20% End-of-Year Promotion and New Developments at SOLVO!

November 23, 2012


Order before December 31st and get a 20% discount on SOLVO's MDR1 and BCRP products*!

*The 20% discount is available for the following products:

  • SB-MDR1-K-VT membrane preparations for Vesicular Transport Assays
  • SB-BCRP-M-VT membrane preparations for Vesicular Transport Assays
  • This Promotion does not apply for Japan!

    Learn more about our drug transporter assay products!


    Drugs as Probe substrates for Uptake and Efflux Transporter Assays

    Regulatory agencies prefer to see assays where drugs instead of physiological substrates or other substrate chemicals are used as probes. This approach has multiple advantages, since the probe – transporter interaction is pharmacologically more relevant and the inhibition assays yield relevant drug – drug interaction data. SOLVO continues the validation process of FDA relevant inhibition assays with clinically relevant drugs as probe substrates.

    Uptake transporter assays validated with clinically relevant drugs:

  • OAT1 Uptake Transporter Assay with Tenofovir as probe substrate
  • OAT3 Uptake Transporter Assay with Methotrexate (MTX) as probe substrate
  • Coming soon:

  • OCT1 and OCT2 Uptake Transporter Assays validated with cimetidine and MPP+ as probe substrates
  • OAT1 and OAT3 Uptake Transporter Assays validated with Chlorothiazide as probe substrates
  • MDCKII-BCRP and Caco2 Monolayer Assays validated with teriflunomide and chlorothiazide as BCRP probe substrates.
  • New Cell Lines and Uptake Inhibition Assays Available

    SOLVO Biotechnology is continuously expanding its portfolio to meet your needs. New uptake inhibition assays available at SOLVO:

    URAT1 Uptake Inhibition Assay

    URAT1 (Urate Anion Exchanger 1), a member of the OAT family is predominantly localized to the apical membrane of renal proximal tubular cells. URAT1 mediates the reabsorption of uric acid, thereby regulating blood uric acid concentrations. Impairment in URAT1 activity, either due to polymorphisms, or drug drug interactions, can have toxicological consequences. Besides uric acid human URAT1 also mediates the uptake of orotate, a precursor of pyrimidine synthesis. URAT1 inhibition assay is now available with both Uric and Orotic acids as probe substrates.

    Learn more about the URAT1 transporter.

    OCT3 Uptake Inhibition Assay

    OCT3 (Organic Cation Transporter 3 / SLC22A3) has broad tissue distribution, including the placenta, liver, kidney, skeletal muscle and small intestine and at low level the brain and lung tissue. The broader distribution of OCT3 contributes to physiological functions such as regulation of the interstitial concentration of monoamine neurotransmitters and cationic drugs in the central nervous system and release of acetylcholine from placenta. The substrate specificity of OCT3 is similar to OCT1 or OCT2, including Type I and II organic cations such as the neurotransmitters noradrenaline, adrenaline, histamine, TEA and the neurotoxin MPP+. In our uptake inhibition assay TEA is used as a probe substrate.

    ASBT Uptake Inhibition Assay

    Apical sodium-dependent bile acid transporter (ASBT, SLC10A2) is a member of the SLC protein family and has important physiological functions as a bile acid transporter. ASBT is expressed in renal proximal tubule cells, enterocytes in the ileum, gallbladder epithelial cells and large cholangiocytes. ASBT is critical for intestinal reabsorption of bile acids in the enterohepatic recirculation and functions to reabsorb the majority of the bile acids undergoing glomerular filtration. Physiological substrates of ASBT include unconjugated bile acids and their glycine and taurine-conjugates. In our uptake inhibition assay Taurocholic acid is used as a probe substrate.

    New page at SOLVO's website introducing the newest developments

    SOLVO is continuously expanding its product and service portfolio, with 10-20 new launches annually. Our focus is to develop new products and services based on the latest results in drug transporter science, the needs of the pharmaceutical industry and suggestion of the various regulatory agencies such as FDA and EMA regarding transporter related drug drug interaction studies.

    You can easily catch up with our latest developments by visiting the webpage dedicated to the newest offerings in our drug transporter assay portfolio.

    For further details contact us at .(JavaScript must be enabled to view this email address)!

    Next entry: New BCRP Probe Substrates

    Previous entry: EMA publishes new Guideline

    More News

    Read all news in the archive